Scott L. Burrows, the chief financial officer of Spyre Therapeutics, Inc. (SYRE -0.89%), sold 7,500 shares of common stock on August 3, according to an SEC Form 4 filing. Transaction summary Metric Value Transaction value $717,000 Shares sold (direct) 7,500 Post-transaction shares (directly held) 97,994 Post-transaction value $9.3 million Transaction value based on SEC Form…